This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Discussing the Phase 3 DAYBREAK study of Zeposia (ozanimod), an oral medication that has been FDA approved for treatment of Multiple Sclerosis.
Ticker(s): BMYWho's the expert?
Institution: University of Maryland Medical System
- Neurologist with a speciality in Multiple Sclerosis and extensive training in all neurological diseases of adults and children.
- Currently manages 80 patients per month with Multiple Sclerosis.
- Able to discuss the Phase 3 DAYBREAK of Zeposia for treatment of Multiple Sclerosis.
Interview Goalthe Phase 3 DAYBREAK study of Zeposia (ozanimod), an oral medication that has been FDA approved for treatment of Multiple Sclerosis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
